DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance

Information source: Biogen
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Multiple Sclerosis

Phase: N/A

Status: Terminated

Sponsored by: Biogen


Phase IV, multi-center, non-treatment, observational, registry study to determine long term effects of AVONEX therapy on EDSS, MRI, QoL, and cognition.

Clinical Details

Official title: Phase IV, Multi-center, Non-treatment, Observational, Registry Study to Determine Long Term Effects of AVONEX Therapy on EDSS, MRI, QoL, and Cognition.

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome:



Secondary outcome:

Quality of Life

Symbol Digit Modality Test

Detailed description: The primary objective of this study is to determine the impact of long term AVONEX treatment on physical status, measured by expanded disability scale score (EDSS), of patients with Multiple Sclerosis (MS) after their first clinical event (clinically isolated syndrome) and Magnetic Resonance Imaging (MRI) consistent with MS. Secondary objectives are to determine the impact of long term therapy with AVONEX® on the following: a) MRI parameters- new or enlarging T2 lesions, T2 lesion volume, T1 lesion volume, brain parenchymal fraction (BPF) b) Quality of Life (QoL): Heath Status Questionnaire (SF-36) c) Symbol Digit Modality Test (SDMT) 2. To determine the long term impact of therapy on the following in patients treated at the onset of clinically isolated event (CIS) 1. EDSS 2. MRI parameters 3. SF-36 4. SDMT 3. To determine early clinical and MRI predictors of disease progression. Approximately 383 patients participated in CHAMPS, the original AVONEX® placebo trial, will be approached for study participation. The patient population will be divided into two cohorts. Cohort 1: Patients that participated in CHAMPS and CHAMPIONS 10 will be approached for study participation at approximately twenty-four CHAMPIONS Continuation investigative sites. Cohort 2: Patients that participated in CHAMPS will be located and approached for study participation. Patient that participated in CHAMPIONS 10 will not be excluded from Cohort 2. Efforts will be made to potentially locate patients through either the original CHAMPS investigative sites, through the Biogen Idec patient services database, and/or a third party (i. e., patient location service vendor) or some combination of the three. . For both cohorts, public databases may be utilized for patient reported death.


Minimum age: 18 Years. Maximum age: 85 Years. Gender(s): Both.


Inclusion Criteria:

- Patients are eligible to be screened for this study if all of the following criteria

are met: 1. All patients must have been originally enrolled in CHAMPS, regardless of randomization arm. Only Cohort 1 patients must have been enrolled in CHAMPIONS 10. 2. Willing and able to provide informed consent (Cohort 1), waiver of informed consent (Cohort 2), or reported patient death through public database search. 3. Ability to read and write English (patient reported assessment tools are in English only). Exclusion Criteria:

- Candidates will be excluded from study screening if any of the following exclusion

criteria exist: 1. Patients not participating in the original CHAMPS study. 2. Alternative diagnosis to MS discovered. 3. Patient unwilling or unable to provide informed consent (Cohort 1) or waiver of informed consent (Cohort 2), as applicable. 4. Any other reasons that, in the opinion of the Investigator (Cohort 1) or Patient Coordination Center (Cohort 2), the patient is determined to be unsuitable for enrollment into this study.

Locations and Contacts

Research Site, Buffalo, New York 14203, United States
Additional Information

Starting date: June 2010
Last updated: August 2, 2012

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017